Therapeutic Program Areas

 

Our research covers a range of diseases, with a particular focus in three major therapeutic areas:

Neuroscience and Mental Health

The neuroscience and mental health TPA encompasses multidisciplinary approaches to unmet medical needs in psychiatry, neurodegeneration, pain, and other mental health disorders.

Cardiovascular and Metabolic Health

The cardiovascular and metabolic health TPA works to develop cardiovascular and metabolic disease therapeutics. Its expertise runs from basic research through to animal disease models and on to translational human disease.

Global Health

The global health TPA aims to improve health & achieve equity in health for all people worldwide, major activities focus on infectious diseases and maternal, child and reproductive health.

Latest news from the TPAs

Dr Greg Stewart, Associate Professor Jess Nithianantharajah and Professor Chris Langmead

Phrenix secures major funding boost from US and Australian venture capital firms to advance new therapeutics for psychiatric disorders

Phrenix Therapeutics, a biotech company focused on next-generation medicines for psychiatric and neurological disorders, has secured investment from specialist biotech venture capital firms Curie.Bio and Brandon Capital.
3 February, 2025 Research
Arthur Christopoulos

Monash Dean named 2024 Fellow of the American Society for Pharmacology and Experimental Therapeutics

Professor Arthur Christopoulos FAA FAHMS has been named a 2024 Fellow of the American Society for Pharmacology and Experimental Therapeutics (ASPET).
28 November, 2024 Research
Monash Parkville Campus

2024 Faculty of Pharmacy and Pharmaceutical Sciences Awards - Celebrating Professional, Research, and Teaching Excellence

The 2024 Faculty of Pharmacy and Pharmaceutical Sciences Awards were held on 27 November and celebrated the outstanding contributions of staff to professional, research and teaching excellence.
28 November, 2024 Research
Abstract Brain

How Australian scientists helped pave the way for a new class of medicines to treat schizophrenia

People living with schizophrenia will have access to a whole new class of medicine following the US Food and Drug Administration (FDA) approval of the drug ‘Cobenfy’.
1 October, 2024 Research
Professor Simon Bell and Dr Amanda Cross

Monash researchers named 2024 Pharmaceutical Society of Australia Fellows

CMUS Professor Simon Bell, and CMUS Research Fellow, Dr Amanda Cross, have both been named recipients of 2024 Pharmaceutical Society of Australia Fellowships.
5 August, 2024 Research
credit to Zeljkosantrac, Getty Images

How to detect adverse events in older people using psychotropic medicines; Australian researchers name top ten signs and symptoms

A new study has revealed the top ten signs and symptoms to monitor for that may help to identify adverse drug events in older people living in long-term care facilities who are using psychotropic medications.
15 July, 2024 Research

Australian scientists develop a new method for the detection of Alzheimer’s

Researchers have developed a new method for the detection of neurodegenerative diseases, such as Alzheimer’s, by “lighting up” clusters of misfolded proteins in the brain.
20 March, 2024 Research
CMUS Team working

Frailty across borders: Deprescribing opportunities in residents of aged care services across Asia, Oceania, and Europe

Monash University-led study identifies opportunities for deprescribing medications that may no longer be necessary among frail residents of aged care services in Asia, Oceania and Europe.
29 February, 2024 Medicine & health
CMUS Team

Australian aged care residents seven times more likely to be taking painkiller medications when compared with Japan

CMUS researchers have found 74% of Australia’s aged care population are prescribed regular painkiller medications and are 30 times more likely to use opioids, compared to Japan.
28 February, 2024 Medicine & health